<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891536</url>
  </required_header>
  <id_info>
    <org_study_id>CRIOAND 0325-N-21</org_study_id>
    <nct_id>NCT04891536</nct_id>
  </id_info>
  <brief_title>Salvage Cryotherapy for Recurrent Prostate Cancer After Radiation Therapy</brief_title>
  <acronym>CRIOAND2021</acronym>
  <official_title>Salvage Cryotherapy for Recurrent Prostate Cancer After Brachytherapy or Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ignacio Puche Sanz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Reina Sofia de Cordoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Virgen de las Nieves</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this project is to establish a shared comprehensive and systematic&#xD;
      protocol for a multicenter prospective registry of patients undergoing salvage cryoablation&#xD;
      of the prostate (SCAP).&#xD;
&#xD;
      Our study hypothesis is that SCAP constitutes an effective and safe approach to treat local&#xD;
      prostate cancer recurrence after brachytherapy or external beam radiation therapy (EBRT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Salvage cryoablation of the prostate has been proposed as an alternative to salvage radical&#xD;
      prostatectomy, as it has a potentially lower risk of morbidity and equal efficacy. A recent&#xD;
      systematic review assessed a total of 32 studies of SCAP (5.513 patients). The overwhelming&#xD;
      majority of patients (93%) received whole-gland SCAP. The adjusted pooled analysis for 2-year&#xD;
      BCR-free survival for SCAP was 67.49% (95% CI: 61.68-72.81%), and for 5-year BCR-free&#xD;
      survival was 50.25% (95% CI: 44.10-56.40%).&#xD;
&#xD;
      Nevertheless, the evidence base relating to the use of SCAP is poor, with significant&#xD;
      uncertainties relating to long-term oncological outcomes. One of the main limitations when&#xD;
      these studies are analyzed is the lack of information about the histopathology both before&#xD;
      starting treatment and at the time of recurrence after cryotherapy. The vast majority only&#xD;
      refer to biochemical-free survival as end point, thus limiting interpretation of real&#xD;
      oncological performance of this technique. Furthermore, side effects vary widely from study&#xD;
      to study and there are uncertainties about the real morbidity associated to cryotherapy in&#xD;
      the salvage setting.&#xD;
&#xD;
      Due to this lack of evidence, the EAU 2021 Guidelines recommend that SCAP should only be&#xD;
      performed in selected patients in experienced centres as part of a clinical trial or&#xD;
      well-designed prospective cohort study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free rate</measure>
    <time_frame>1 year</time_frame>
    <description>absence of disease in follow-up biopsy AND PET/PSMA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADT-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Absence of androgen deprivation therapy need during follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of incontinence</measure>
    <time_frame>1 year</time_frame>
    <description>Measured by International Consultation on Incontienence Questionnaire short-form (ICIQ-SF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of sexual disfunction</measure>
    <time_frame>1 year</time_frame>
    <description>Measured by International Index Erectile Function (IIEF-25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on urinary symptoms</measure>
    <time_frame>1 year</time_frame>
    <description>Measured by International Prostate Symptoms Score (IPSS) and uroflowmetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical free survival</measure>
    <time_frame>5 years</time_frame>
    <description>PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Metastasis detected in novel imaging modalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of mpMRI and PET-CT for the detection of clinically significant recurrence.</measure>
    <time_frame>1 year</time_frame>
    <description>Related to the histopathology observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of metastasis detected by PET-CT</measure>
    <time_frame>1 year</time_frame>
    <description>Metastais detected</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Cryotherapy</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with histologically confirmed recurrent prostate cancer after primary radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Salvage cryoablation of the prostate (SCAP)</intervention_name>
    <description>Cryotherapy of the prostate through transperineal freeezing needles</description>
    <arm_group_label>Patients with histologically confirmed recurrent prostate cancer after primary radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with local recurrence (with histological confirmation) after treatment with&#xD;
             radiotherapy or brachytherapy without evidence of distant involvement evaluated with&#xD;
             PET/PSMA (if not available then Fluciclovine PET/CT or choline PET/CT must be&#xD;
             performed).&#xD;
&#xD;
          -  Life expectancy &gt;10 years&#xD;
&#xD;
          -  Prostate volume &lt; 100cc&#xD;
&#xD;
          -  PSA&lt;10 ng/mL&#xD;
&#xD;
          -  mpMRI + fusion/systematic biopsy ≤cT3a without affecting the bladder neck or the&#xD;
             membranous urethra&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with clinically confirmed distant metastasis&#xD;
&#xD;
          -  Any previous major rectal surgery&#xD;
&#xD;
          -  Clinically significant lower urinary tract or rectal anomalies&#xD;
&#xD;
          -  Existing urethral, rectal, or bladder fistulae&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enrique Gómez-Gómez</last_name>
    <phone>958 56 76 65</phone>
    <email>enriquegomezgomez@yahoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gómez-Gómez</last_name>
      <phone>958 56 76 65</phone>
      <email>enriquegomezgomez@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Enrique Gómez-Gómez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Puche-Sanz</last_name>
      <phone>958 67 56 37</phone>
      <email>nacho.puchesanz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ignacio Puche-Sanz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Virgen de las Nieves</investigator_affiliation>
    <investigator_full_name>Ignacio Puche Sanz</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>PSMA/PET-CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

